Recent Updates
Recently added Catalysts
AMIX Positive Sentiment Score: 75/100

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Key Takeaway: Autonomix Medical, Inc. has published the latest CEO Corner segment on its website. In this segment, CEO Brad Hauser discusses the company's advancements over the past year and shares his insights regarding future developments. The company is focused on its innovative medical technology poised to improve the diagnosis and treatment of diseases affecting the nervous system, specifically targeting conditions like pancreatic cancer. The technology, still in investigational stages, offers significant sensitivity improvements over existing methods.

Market Sentiment Analysis

POSITIVE FACTORS

  • Announcement of the next CEO Corner segment indicates proactive communication.
  • CEO Brad Hauser expressed optimism about the company's progress and future.
  • Autonomix's innovative technology shows promise for diagnosing and treating nervous system diseases.

Full Press Release Details

THE WOODLANDS, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, reflected on the Company’s progress made over the last year and shared insight into the year ahead.
The CEO Corner segment is now available here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact

Tags

next CEO Corner segment
medical device company
innovative technologies

Frequently Asked Questions

What is the focus of Autonomix Medical, Inc.?

Autonomix focuses on innovative technologies to improve diagnosis and treatment of nervous system diseases.

What technology does Autonomix develop?

Autonomix develops a catheter-based microchip sensing array for detecting neural signals.

What condition is Autonomix's initial technology targeting?

The initial technology targets the treatment of pain associated with pancreatic cancer.

Is Autonomix's technology approved for marketing?

No, Autonomix's technology is investigational and not yet cleared for marketing in the U.S.

Last updated: Dec 23, 2024